Loading
In HER2-positive salivary duct carcinoma, an aggressive salivary cancer resembling breast cancer, trastuzumab plus docetaxel shrank tumours in 70 percent of patients, establishing HER2 testing and targeting in the disease.
Single-arm phase 2 study of 57 patients with HER2-positive locally advanced, recurrent or metastatic salivary duct carcinoma treated with trastuzumab and docetaxel.
Objective response was 70.2 percent with a median progression-free survival of 8.9 months and median overall survival of 39.7 months, with toxicity similar to the regimen's use in breast cancer.
HER2 testing is standard in salivary duct carcinoma and trastuzumab-docetaxel a first-line option for HER2-positive advanced disease, with trastuzumab deruxtecan available at progression.
Shares Salivary duct carcinoma, Journal of Clinical Oncology.
Shares Docetaxel, Journal of Clinical Oncology.
Shares Trastuzumab, Journal of Clinical Oncology.
Shares Trastuzumab, Docetaxel.
Shares Trastuzumab, Journal of Clinical Oncology.
Shares Trastuzumab, Docetaxel.
Shares Trastuzumab, Docetaxel.
Shares Trastuzumab, Docetaxel.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/